NZ757938B2 - Subcutaneous administration of a p2y12 receptor antagonist - Google Patents
Subcutaneous administration of a p2y12 receptor antagonist Download PDFInfo
- Publication number
- NZ757938B2 NZ757938B2 NZ757938A NZ75793818A NZ757938B2 NZ 757938 B2 NZ757938 B2 NZ 757938B2 NZ 757938 A NZ757938 A NZ 757938A NZ 75793818 A NZ75793818 A NZ 75793818A NZ 757938 B2 NZ757938 B2 NZ 757938B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- administration
- use according
- medicament
- administered
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The present invention relates to a P2Y12 receptor antagonist 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester or a pharmaceutically acceptable salt thereof, for use as a medicament by subcutaneous administration.
Claims (18)
1. Use of a P2Y receptor antagonist, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of a disease, wherein the disease is selected from acute arterial thromboses and acute venous 5 thromboses; wherein the P2Y receptor antagonist is 4-((R){[6-((S)methoxy- pyrrolidinyl)phenyl-pyrimidinecarbonyl]-amino}phosphono-propionyl)- piperazinecarboxylic acid butyl ester; and wherein the medicament is for administration and/or is to be administered to a patient by subcutaneous administration. 10
2. Use according to claim 1, wherein the disease is selected from the group consisting of acute coronary syndromes, myocardial infarction, peripheral ischaemia, amaurosis, sudden cardiac death, ischaemic stroke and transient ischaemic attack.
3. Use according to claim 1, wherein the disease is acute coronary syndromes.
4. Use according to claim 1, wherein the disease is myocardial infarction. 15
5. Use according to any one of claims 1 to 4, wherein the medicament is for administration and/or is to be administered prior to hospitalization.
6. Use according to claim 5, wherein the medicament is for administration and/or is to be administered by patient self-administration.
7. Use of a P2Y receptor antagonist, or a pharmaceutically acceptable salt thereof, 20 for the preparation of a medicament for the emergency treatment of suspected acute coronary syndromes by patient self-administration prior to hospitalization; wherein the P2Y receptor antagonist is 4-((R){[6-((S)methoxy-pyrrolidinyl)- 2-phenyl-pyrimidinecarbonyl]-amino}phosphono-propionyl)-piperazine carboxylic acid butyl ester; and wherein the medicament is for administration and/or 25 is to be administered to a patient by subcutaneous administration.
8. Use according to any one of claims 1 to 7, wherein the amount of 4-((R){[6-((S)- 3-methoxy-pyrrolidinyl)phenyl-pyrimidinecarbonyl]-amino}phosphono- propionyl)-piperazinecarboxylic acid butyl ester that is for administration and/or is to be administered is comprised between 1 mg and 75 mg per administration. 30
9. Use according to any one of claims 1 to 7, wherein the amount of 4-((R){[6-((S)- 3-methoxy-pyrrolidinyl)phenyl-pyrimidinecarbonyl]-amino}phosphono- propionyl)-piperazinecarboxylic acid butyl ester that is for administration and/or is to be administered is comprised between 5 mg and 35 mg per administration.
10. Use according to any one of claims 1 to 7, wherein the amount of 4-((R){[6-((S)- 35 3-methoxy-pyrrolidinyl)phenyl-pyrimidinecarbonyl]-amino}phosphono- propionyl)-piperazinecarboxylic acid butyl ester that is for administration and/or is to be administered is 16 mg per administration.
11. Use according to any one of claims 1 to 10, wherein the P2Y receptor antagonist, optionally together with one or more therapeutically inert excipient(s), is dissolved in 5 a pharmaceutically acceptable liquid to give a solution and wherein the volume of the solution that is for administration and/or is to be administered is comprised between 0.1 mL and 3.0 mL per administration.
12. Use according to claim 11, wherein the pharmaceutically acceptable liquid is water.
13. Use according to any one of claims 1 to 12, wherein the medicament is for 10 administration and/or is to be administered in a bolus injection.
14. Use according to any one of claims 1 to 13, wherein an inhibition of platelet aggregation of at least 75% is reached within 30 min after onset of administration of the P2Y receptor antagonist in at least 80% of the patients.
15. Use according to any one of claims 1 to 13, wherein an inhibition of platelet 15 aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y receptor antagonist in at least 80% of the patients.
16. Use of 4-((R){[6-((S)methoxy-pyrrolidinyl)phenyl-pyrimidinecarbonyl]- amino}phosphono-propionyl)-piperazinecarboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for 20 the treatment of a disease, wherein the disease is selected from the group consisting of acute coronary syndromes, myocardial infarction, peripheral ischaemia, amaurosis, sudden cardiac death, ischaemic stroke and transient ischaemic attack, and wherein the medicament is for administration and/or is to be administered to a patient by subcutaneous administration. 25
17. Use of the P2Y12 receptor antagonist 4-((R){[6-((S)methoxy-pyrrolidinyl) phenyl-pyrimidinecarbonyl]-amino}phosphono-propionyl)-piperazine carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the emergency treatment of suspected acute coronary syndromes by patient self-administration prior to hospitalization; wherein 30 the medicament is to be administered to a patient by subcutaneous administration.
18. A use according to any one of claims 1 to 17, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017056175 | 2017-03-15 | ||
| PCT/EP2018/056372 WO2018167139A1 (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ757938A NZ757938A (en) | 2024-07-05 |
| NZ757938B2 true NZ757938B2 (en) | 2024-10-08 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150174123A1 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury | |
| JP2018197248A (en) | Method for treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| ES2704229T3 (en) | Selective AT2 receptor agonists for use in the treatment of cachexia | |
| JP2020510043A5 (en) | ||
| EP2988750B9 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| KR101176110B1 (en) | Prevention and / or Treatment of Portal Hypertension | |
| JP2018533601A (en) | L-ornithine phenyl acetate preparation | |
| KR20120089623A (en) | Treating patients with intravenous ibuprofen | |
| CN102802618B (en) | Therapeutic combinations of nicotinic acid and meldonium | |
| CN113876775A (en) | Use of sinomenine or its pharmaceutically acceptable salt as medicine for treating arterial pulmonary hypertension | |
| CN108472333B (en) | combination | |
| NZ757938B2 (en) | Subcutaneous administration of a p2y12 receptor antagonist | |
| NZ757938A (en) | Subcutaneous administration of a p2y12 receptor antagonist | |
| JP6629850B2 (en) | General-purpose cardioplegic solution (variant) | |
| EP2925128A1 (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure | |
| CN110292637B (en) | A pharmaceutical composition for preventing and treating hypertension | |
| CN103405438B (en) | Trapidil or the application of its pharmaceutically acceptable salt in preparation control pulmonary hypertension medicine | |
| JP2016510738A5 (en) | ||
| CN104644668A (en) | First-aid plasma substitute medicine composition and preparation method thereof | |
| US11413273B2 (en) | Prophylactic or therapeutic agent for pulmonary hypertension comprising unsaturated 5-membered heterocycle-containing compound | |
| WO2018219189A1 (en) | Application of cefmetazole in preparation of medicine for preventing/treating pulmonary hypertension | |
| JP6935930B2 (en) | Prophylactic or therapeutic agent for pulmonary hypertension containing crude drug ingredients | |
| US20120277264A1 (en) | Antithrombotic agent | |
| CN117243947A (en) | Application of daphnetin and combinations containing the same in the preparation of drugs for diabetic complications | |
| RU2582219C2 (en) | Artificial plasma extender |